EPCAM and cancer: As observed by our recent in vitro data, recombinant EpCAM-enriched cell culture medium, with similar concentrations than those reached in ascites, counteracts the ADCC effects of catumaxomab on HEK transfected EpCAM cancer cells showing that high amounts of sEpCAM in ascites impede the full effect of catumaxomab by saturating its EpCAM-binding Fab fragment [12].